Drug research

IHL-42X (Optimal Dose)

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Phase 3 Investigational Product - IHL-42X

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSANCT06146101	Incannex Healthcare Ltd	Phase 2, Phase 3	Completed	2025-05-20Actual

Incannex Healthcare LtdCompletedPrimary completion: 2025-05-20 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.